Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey

Gathirua-Mwangi, Wambui G.; Monahan, Patrick O.; Murage, Mwangi J; Zhang, Jianjun

doi:10.1007/s10552-016-0843-1

Cited by 47 publications

(56 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous study by Gathirua-Mwangi et al assessed whether metabolic syndrome, as well as the individual markers, were associated with total cancer mortality in the NHANES III Study. The presence of metabolic syndrome (yes/no) was associated with a 33% increase in total cancer mortality 37 . In terms of the individual components, the study displayed that only systolic BP and serum glucose were associated with an increased risk of death from total cancer 37 .…”

Section: Discussionmentioning

confidence: 99%

Multi-Systemic Biological Risk and Cancer Mortality: The NHANES III Study

Acheampong

Jiang

Ziogas

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Multi-systemic biological risk (MSBR), a proxy for allostatic load, is a composite index of biomarkers representing dysregulation due to responses to chronic stress. this study examined the association of an MSBR index with cancer mortality. the sample included n = 13,628 adults aged 20-90 from the NHANES III Linked Mortality File (1988)(1989)(1990)(1991)(1992)(1993)(1994). The MSBR index included autonomic (pulse rate, blood pressure), metabolic (HoMA ir , triglycerides, waist circumference), and immune (white blood cell count, C-reactive protein) markers. We fit Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CI) of overall cancer mortality risk, according to quartiles (q) of the index. In multivariable models, compared to those in q1, q4 had a 64% increased risk for cancer mortality (HR = 1.64, 95% CI:1.13-2.40). The immune domain drove the association (HR per unit = 1.19, 95% CI:1.07-1.32). In stratified analyses, the HR for those with a BMI ≥ 25 was 1.12 per unit (95% CI:1.05-1.19) and those with a BMI < 25 was 1.04 per unit (95% CI:0.92-1.18). MSBR is positively associated with risk for cancer mortality in a US sample, particularly among those who are overweight or obese. The utilization of standard clinical measures comprising this index may inform population cancer prevention strategies.Multi-systemic biological risk (MSBR) is a proxy for allostatic load (AL). It is a metric of health risk that captures the complex biological cascade that occurs in autonomic, metabolic, and immune domains in response to chronic environmental and psychosocial stress 1-3 . The validity of the AL construct is established and demonstrates common variance and statistical coherence between, prominent primary mediators of the stress response (i.e., stress hormones), and secondary mediators reflecting the resulting biological alterations in autonomic, metabolic, and immune domains that accumulate over time [4][5][6][7][8] . Importantly, summary AL indices have demonstrated a non-additive, stronger magnitude of association with outcomes compared with the individual components of the index 9 .Previous research has shown that autonomic, metabolic, and immune disorders, share common risk factors with cancer outcomes 10-12 . Moreover, there is a strong physiological link between over-activation of the stress response and regulation of the tumor microenvironment [13][14][15] . In mechanistic animal studies where stress can demonstrably be reproduced, chronic responses to stress influence processes involved in tumorigenesis [16][17][18][19] . However, observational studies assessing self-report of stressful life events and cancer outcomes have generally been inconsistent [20][21][22][23][24][25] .Epidemiological studies show positive associations between higher levels of AL indices and cardiovascular disease (CVD), as well as mortality risk 26,27 . However, we are not aware of any studies that have examined an index of AL with cancer outcomes. With cancer being the second leading cause of de...

show abstract

Section: Discussionmentioning

confidence: 99%

Multi-Systemic Biological Risk and Cancer Mortality: The NHANES III Study

Acheampong

Jiang

Ziogas

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…30 The conflicting results may be in part because the cancers summed up may vary across the studies. Therefore, using total cancer mortality as an outcome may attenuate the true relationship of MetS and cancer mortality in part because it includes lung cancer which has not been linked to MetS 31 and because of the differences in risk factors associated with each cancer site. To address this limitation, we assessed the relationship of MetS with mortality from cancers that have strongly been linked to obesity.…”

Section: Discussionmentioning

confidence: 99%

“…A total of 400 cases of cancer deaths were documented from, the 10,014 participants during a follow-up of 132,557 person-years. The follow-up period for each of the subjects was calculated as the time from the date of health examination to the occurrence of cancer death or the censor date (December 31,2006), whichever occurred first. The anatomic sites of cancer for the 400 cases included total-obesitylinked cancers (n 5 118): breast (n 5 55), colorectal (n 5 33) pancreas (n 5 18) and endometrial (n 5 12).…”

Section: Study Populationmentioning

confidence: 99%

Associations of metabolic syndrome and C‐reactive protein with mortality from total cancer, obesity‐linked cancers and breast cancer among women in NHANES III

Gathirua-Mwangi

Song

Monahan

et al. 2018

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Although metabolic syndrome (MetS) is a prognostic factor for cancer occurrence, the association of MetS and cancer mortality remains unclear. The purpose of this study was to evaluate whether MetS, components of MetS and C-reactive protein (CRP) are associated with cancer mortality in women. A total of 400 cancer deaths, with 140 deaths from obesity-linked-cancers (OLCas), [breast (BCa), colorectal, pancreatic and endometrial], linked through the National Death Index, were identified from 10,104 eligible subjects aged ≥18 years. Cox proportional hazards regression was used to estimate multivariable-adjusted hazard ratios (HR) for cancer mortality. MetS was associated with increased deaths for total cancer [HR = 1.33, 95% confidence interval (CI) 1.04-1.70] and BCa [HR = 2.1, 95% CI, 1.09-4.11]. The risk of total cancer [HR = 1.7, 95% CI, 1.12-2.68], OLCas [HR = 2.1, 95% CI, 1.00-4.37] and BCa [HR = 3.8, 95% CI, 1.34-10.91] mortality was highest for women with all MetS components abnormal, compared to those without MetS. Linear associations of blood-pressure [HR = 2.5, 1.02-6.12, Quartile (Q) 4 vs Q1, p trend = 0.004] and blood-glucose [HR = 2.2, 1.04-4.60, Q4 vs. Q1, p trend = 0.04] with total-OLCas mortality were observed. A threefold increased risk of BCa mortality was observed for women with enlarged waist circumference, ≥100.9 cm, [HR = 3.5, 1.14-10.51, p trend = 0.008] and in those with increased blood glucose, ≥101 mg/dL, [HR = 3.2, 1.11-9.20, p trend = 0.03] compared to those in Q1. None of the components of MetS were associated with total-cancer mortality. CRP was not associated with cancer mortality. In conclusion, MetS is associated with total-cancer and breast-cancer mortality, with waist circumference, blood pressure and blood glucose as independent predictors of OLCas and BCa mortality.

show abstract

“…Metabolic syndrome is also associated with an increased risk of type 2 diabetes, cardiovascular morbidity, and mortality [2][3][4][5][6][7]. Furthermore, there is an association between MetS and increased total cancer mortality [8,9]. The incidence of metabolic syndrome and the pathophysiological mechanisms underlying its development are still not fully understood.…”

Section: Introductionmentioning

confidence: 99%

The roles of vaspin, chemerin, and omentin in the determination of metabolic syndrome

Suliga¹,

Wawszczak²,

Głuszek³

2018

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is defined as multiple risk factors including abdominal obesity, dyslipidaemia, abnormal glycaemia, and elevated blood pressure. The incidence of MetS and pathophysiological mechanisms underlying its development are still not fully understood. It is thought that the occurrence of MetS arises from the complex relationship between genetic and environmental factors. The aim of the study was to overview and summarise current knowledge regarding genetic determinants of MetS. Also analysed were the relationship between polymorphisms of the genes encoding selected adipokines (vaspin, chemerin, omentin) and the risk of MetS, as well as other metabolic disorders. The precise determination of MetS genotype is difficult because metabolic syndrome occurrence is a combination of multiple risk factors. A thorough understanding of pathomechanisms of MetS, involving selected adipokines, may in the future allow the use of these adipokines as potential biomarkers of metabolic disorder risk.

show abstract

Metabolic syndrome and total cancer mortality in the Third National Health and Nutrition Examination Survey

Cited by 47 publications

References 48 publications

Multi-Systemic Biological Risk and Cancer Mortality: The NHANES III Study

Multi-Systemic Biological Risk and Cancer Mortality: The NHANES III Study

Associations of metabolic syndrome and C‐reactive protein with mortality from total cancer, obesity‐linked cancers and breast cancer among women in NHANES III

The roles of vaspin, chemerin, and omentin in the determination of metabolic syndrome

Contact Info

Product

Resources

About